For example, in HER2-positive breast cancer, low expression of MTFP1 is associated with resistance to chemotherapeutic drugs; In non-small cell lung cancer, the dysfunction of MTFP1 leads to the cancer cells' resistance to radiotherapy (Meng et al., 2024). This evidence concerns the gene ERBB2 and breast carcinoma.